These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29941343)

  • 21. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
    Kawahara T; Kojima T; Kandori S; Kurobe M; Yoshino T; Kimura T; Nagumo Y; Ishituka R; Mitsuzuka K; Narita S; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Miyazaki J; Nishiyama H
    PLoS One; 2019; 14(8):e0220173. PubMed ID: 31369573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.
    Kim Y; Ju H; Yoo SY; Jeong J; Heo J; Lee S; Park JM; Yoon SY; Jeong SU; Lee J; Yun H; Ryu CM; Lee J; Nam YJ; Kwon H; Son J; Jeong G; Oh JH; Sung CO; Jeong EM; An J; Won S; Hong B; Lee JL; Cho YM; Shin DM
    Cell Rep Med; 2023 Oct; 4(10):101224. PubMed ID: 37797616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
    Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
    Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
    Noel N; Couteau J; Maillet G; Gobet F; D'Aloisio F; Minier C; Pfister C
    Anticancer Res; 2015 Sep; 35(9):4915-21. PubMed ID: 26254388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer.
    Murphy N; Shih AJ; Shah P; Yaskiv O; Khalili H; Liew A; Lee AT; Zhu XH
    Oncotarget; 2022 Nov; 13():1188-1200. PubMed ID: 36322407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.
    Neuzillet Y; van Rhijn BW; Prigoda NL; Bapat B; Liu L; Bostrom PJ; Fleshner NE; Gallie BL; Zlotta AR; Jewett MA; van der Kwast TH
    Virchows Arch; 2014 Aug; 465(2):207-13. PubMed ID: 24880661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
    López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
    Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations of
    Yang Z; Shen Z; Jin D; Zhang N; Wang Y; Lei W; Zhang Z; Chen H; Naz F; Xu L; Wang L; Wang S; Su X; Yu C; Li C
    J Clin Transl Res; 2021 Jun; 7(3):386-413. PubMed ID: 34239995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer.
    Wang QY; Zhao Y; Zhang R
    Minerva Med; 2015 Dec; 106(6):333-7. PubMed ID: 26542242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
    Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
    Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
    Al-Ahmadie HA; Iyer G; Janakiraman M; Lin O; Heguy A; Tickoo SK; Fine SW; Gopalan A; Chen YB; Balar A; Riches J; Bochner B; Dalbagni G; Bajorin DF; Reuter VE; Milowsky MI; Solit DB
    J Pathol; 2011 Jun; 224(2):270-9. PubMed ID: 21547910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
    Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
    Blinova E; Samishina E; Deryabina O; Blinov D; Roshchin D; Shich E; Tumutolova O; Fedoseykin I; Epishkina A; Barakat H; Kaprin A; Zhandarov K; Perepechin D; Merinov D; Brykin G; Arutiunian K; Serebrianyi S; Mirontsev A; Kozdoba A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery.
    Zhu F; Zhang Y; Shi L; Wu CL; Chen SQ; Zheng H; Song DK
    Medicine (Baltimore); 2019 Aug; 98(32):e16451. PubMed ID: 31393349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
    PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
    Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.